New cell therapy aims to halt kidney decline in diabetics
Disease control
Recruiting now
This study tests an experimental cell therapy called REACT (rilparencel) in 685 adults with type 2 diabetes and chronic kidney disease. The goal is to see if up to two injections can slow the loss of kidney function compared to a sham procedure. Participants will be followed for …
Phase: PHASE3 • Sponsor: Prokidney • Aim: Disease control
Last updated May 17, 2026 11:38 UTC